| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-36 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-36 |
| filingDate |
2021-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_48f52e992000ad89da2b7c1f6183b606
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0c154a5890245cbb7077e196fb9468b4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96397adf5aad1f2638ea100706117ba9 |
| publicationDate |
2022-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2022013809-A2 |
| titleOfInvention |
USE OF mGluR5 ANTAGONISTS |
| abstract |
The invention relates to the use of mavoglurant, or a pharmaceutically acceptable salt thereof: in the reduction of opioid use by an opioid use disorder patient; in preventing relapse into opioid use by an opioid use disorder patient; in the promotion of opioid abstinence by an opioid use disorder patient; in the treatment of the symptoms of depression or anxiety associated with opioid use disorder. |
| priorityDate |
2020-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |